Induction chemotherapy followed by cisplatin or cetuximab concomitant to radiotherapy for laryngeal/hypopharyngeal cancer: Long-term results of the TREMPLIN randomised GORTEC trial.

Fiche publication

Date publication

mai 2020

Journal

European journal of cancer (Oxford, England : 1990)

Auteurs

Membres identifiés du Cancéropôle Est :
Dr GEOFFROIS Lionnel

Tous les auteurs :
Janoray G, Pointreau Y, Alfonsi M, Sire C, Geoffrois L, de Raucourt D, Bardet E, Calais MH, Garaud P, Calais G

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/32454417

Résumé

In Europe, induction chemotherapy (ICT) followed by radiotherapy is preferred to conventional chemoradiotherapy to avoid total laryngectomy in patients with laryngeal/hypopharyngeal cancer. In comparison with conventional radiotherapy, bioradiotherapy with cetuximab significantly improves locoregional control rates (LCRs) and overall survival (OS) without any increase in unmanageable toxicity.